Purpose: Hypoxic-ischemic encephalopathy is a significant cause of neonatal morbidity and mortality. Erythropoietin (EPO) is emerging as a therapeutic candidate for neuroprotection. Therefore, this study was designed to determine the neuroprotective role of recombinant human EPO (rHuEPO) and the possible mechanisms by which mitogen-activated protein kinase (MAPK) signaling pathway including extracellular signal-regulated kinase (ERK1/2), JNK, and p38 MAPK is modulated in cultured cortical neuronal cells and astrocytes. Methods: Primary neuronal cells and astrocytes were prepared from cortices of ICR mouse embryos and divided into the normoxic, hypoxia (H), and hypoxia-pretreated with EPO (H+EPO) groups. The phosphorylation of MAPK pathway was quantified using western blot, and the apoptosis was assessed by caspase-3 measurement and terminal deoxynucleotidyl transferase dUTP nick end labeling assay. Results: All MAPK pathway signals were activated by hypoxia in the neuronal cells and astrocytes (P<0.05). In the neuronal cells, phosphorylation of ERK-1/-2 and apoptosis were significantly decreased in the H+EPO group at 15 hours after hypoxia (P<0.05). In the astrocytes, phosphorylation of ERK-1/-2, p38 MAPK, and apoptosis was reduced in the H+EPO group at 15 hours after hypoxia (P<0.05). Conclusion: Pretreatment with rHuEPO exerts neuroprotective effects against hypoxic injury reducing apoptosis by caspase-dependent mechanisms. Pathologic, persistent ERK activation after hypoxic injury may be attenuateed by pretreatment with EPO supporting that EPO may regulate apoptosis by affecting ERK pathways.
Introduction
Hypoxic-ischemic encephalopathy (HIE) is one of the most important causes of neonatal brain injury. Despite the introduction of hypothermia treatment, HIE still contributes to significant morbidity and mortality in newborn infants 1, 2) . Recently, the progress in understanding the cellular cascades that mediate brain damage after HIE enables to identify the therapeutic target 3, 4) . This advances led to active research for intervention to enhance neuroprotection 2) . Among, erythropoietin (EPO) has attracted more attention as a neuroprotective agent because it is already used safely to treat anemia even in newborn infants [5] [6] [7] [8] [9] . EPO is originally a central regulator of erythropoiesis. However, EPO and its receptor (EPOR) also express in nonhematopoietic cells, such as cells of neural origin, and exerts neuroprotective effects 5, [10] [11] [12] . EPOR is associated with Janus kinase 2 tyrosine kinases with cell-specific downstream transduction pathways including signal transducers and activators of transcription-5, phosphatidylino sitol-3-kinase/ protein kinase B, nuclear factor kappa B, and mitogen-activated protein kinase (MAPK) 5, 13, 14) . With EPO binding to EPOR, activation of these downstream pathways have been implicated in the regulation of gene expression leading to neuro protec tion 5, 10, 15) . Among these pathways, the MAPK signaling pathways are less well characterized, and limited information on the involvement of MAPK in the mechanisms underlying the EPO-induced neuroprotection is available. MAPK pathways are also known to in volve in neuronal cell injury including hypoxic-ischemia [16] [17] [18] [19] [20] [21] . However, the effect of EPO on MAPK was little known.
Therefore, this study is designed to determine whether EPO has neuroprotective effects against hypoxic injury through cell apop tosis assays. Also, it examined how EPO regulates apoptosis in the MAPK signaling pathway including extracellular signalregulated kinase (ERK1/2), p38 MAPK and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in the cultured cortical neuronal cells and astrocytes.
Materials and methods

Materials
Recombinant human EPO (rHuEPO) was purchased from CJ Cheiljedang Corporation (Seoul, Korea). Poly-D-lysine was from Sigma (Saint Louis, MO, USA), and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) was purchased from Duchefa Biochemie (Haarlem, the Netherlands). Hanks' balanced salt solution (HBSS), Neurobasal medium, B27 supplement, glutamax I, and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid were obtained from GibcoBRL (Grand Island, NY, USA). Dulbecco's modified eagle's medium (DMEM, high glucose-4,500 mg/L, low glucose-1,000 mg/L), fetal bovine serum (FBS), phos phate-buffered saline (PBS), penicillin-strep tomycin, and trypsin-ethylenediaminetetraacetic acid (EDTA) were purchased from Hyclone Laboratories (Logan, UT, USA). Albumin bovine was obtained from Affymetrix (Santa Clara, CA, USA). Antibodies against phospho-p44/42MAPK (p-ERK1/2), p44/ 42MAPK (ERK1/2), phospho-p38 MAPK (p-p38 MAPK), p38 MAPK, phospho-SAPK/JNK (p-SAPK/JNK), SAPK/JNK were all pur chased from Cell Signaling Technologies (Beverly, MA, USA). Secondary goat anti-rabbit IgG-horseradish peroxidase (HRP) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Clarity Western Enhanced Chemiluminescence (ECL) Substrate was purchased from Bio-Rad Laboratories (Hercules, CA, USA).
Primary culture of neuronal cells and astrocytes
This study was performed under the approved animal use guidelines of the Catholic University of Daegu, DCIAFCR-150910-6-Y. Primary neuronal cells from cerebral cortices were prepared as previously described 22) . Embryonic day 16 mice were harvested by cesarean section from anesthetized pregnant ICR mice. Cerebral cortices were isolated and dissociated by trypsin diges tion at 37°C for 1 minute. After washing with HBSS, the cells were triturated with a fire-polished Pasteur pipette. The cell suspension was centrifuged at 1,000 rpm at 25°C for 5 minutes. The pellet was resuspended in Neurobasal medium supplemented with 2% B 27 and 0.5 mM glutamax, 100-U/mL penicillin, and 100-lg/mL streptomycin. The cell suspension was filtered through a 70-μm strainer. The cells were seeded at a density of 2×10 6 cells/mm2 in each dish precoated with 50-μg/mL poly-D-lysine. Cul tures were maintained in a Neurobasal medium at 37°C in 95% humidified air and 5% CO 2 . Three days after plating, the medium was changed. Fifty percent of the medium was changed twice per week. Primary astrocytes were prepared from postnatal day 1 (P1) or 2 (P2) ICR mouse pups as previously described 23) . Cerebral cortices were isolated and dissociated by trypsin digestion at 37°C for 5 minutes. After washing with HBSS, the cells were titrated with a fire-polished Pasteur pipette. The cell suspension was centrifuged at 1,000 rpm at 25°C for 5 minutes. The pellet was resuspended astrocyte culture medium (DMEM, high glucose+10% FBS+1% penicillin/streptomycin). The cell suspension was filtered through a 70-μm strainer. Cells were seeded in T75 flasks precoated with 50 μg/mL poly-D-lysine. Cultures were maintained in culture medium at 37°C in 95% humidified air and 5% CO 2 . After 7 to 8 days, the microglial cells were removed by shaking the T75 flask (at 180 rpm) for 30 minutes in a shaker water bath to obtain purified astrocytes. The supernatant was removed, and fresh culture medium was added to the T75 flask. Then the flask was shaken for 6 hours at 240 rpm to detach the oligodendrocytes from the astrocytes layer. The T75 flask was washed once with PBS and treated with 0.25% trypsin-EDTA. After the astrocytes detached from the T75 flask, they were plated in dishes and in cubated at 37°C in 95% humidified air and 5% CO 2 . The medium was changed twice per week.
MTT assay
In the first set of experiments, cell viabilities were measured by the MTT assay to determine the optimum concentration. Cells were plated in 96-well plates and treat with different concentrations of EPO for 48 hours before a hypoxic insult. The medium Korean J Pediatr 2017;60(6):181-188 was removed and replaced with the 0.5-mg/mL MTT (final concentration). After incubation for 6 hours and 15 hours, at 37 °C in the dark, the MTT solution was removed, and the formazan dye was extracted with 100-μL dimethyl sulfoxide. Absorbance was measured with a microtiter plate enzyme-linked immunosorbent assay reader at 540 nm.
Hypoxia experiments
In the second set of experiments, cells were assigned into the normoxic (N, n=4) group, hypoxia (H, n=4) group, and hypoxiapretreated with EPO (H+EPO, n=4) group. In the N group, the medium was replaced with DMEM with high glucose and then incubated under normoxic conditions (95% humidified air and 5% CO 2 ) at 37°C for 6 hours or 15 hours. This group was used as a negative control during the process. In the H group, the medium was replaced with DMEM containing low glucose. Afterward, the cells were placed in a hypoxia chamber (Billups-Rothenberg Inc., San Diego, CA, USA) and flushed with 1% O 2 (premixed 1% O 2 , 5% CO 2 , 94% N 2 ) at the rate of 30 L/min for 4 minutes. In the H+EPO, the medium was replaced with DMEM containing low glucose and then pretreated with 0.1 U/mL (neuronal cells) or 10 U/mL (astrocytes) for 48 hours. The chamber was sealed and incubated at 37°C for 6 hours or 15 hours.
Terminal deoxynucleotidyl transferase dUTP nick end label ing assay
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) analysis was performed to measure the degree of cellular apoptosis using an in situ ApoBrdU DNA fragmentation assay kit (BioVision, Mountain View, CA, USA), following the manufacturer's instructions. Cell pellets were harvested, washed twice with PBS, and fixed in 1% paraformaldehyde for 15 minutes on ice. After washing with PBS, the cells were incubated with 70% ethanol for a minimum of 30 minutes on ice. The ethanol was carefully aspirated, and the cells were washed with Wash Buffer. Then, the cells were incubated with DNA Labeling Solution for 60 minutes at 37°C. After rinsing with Rinse Buffer, the cells were incubated with the Antibody Solution for 30 minutes at room temperature (RT) in the dark. Thirty minutes after the incubation was complete, Propidium Iodide/RNase A solution was added to the cells, and the cells were incubated for 30 minutes at RT in the dark. Cellular fluorescence was then measured using the Gallios Flow Cytometer (Beckman Coulter, Brea, CA, USA). The 2 dyes in use were propidium iodide (for total cellular DNA) and fluorescein (for apoptotic cells).
Caspase3 activation
The activity of caspase-3 was measured using a colorimetric assay kit (Biovision, San Francisco Bay Area, CA, USA) according to the manufacturer's instructions. Cultured cells were concentrated at 300×g for 5 minutes. The pellet was resuspended in a cell lysis buffer and incubated on ice for 10 minutes. The cells were centrifuged for 1 minute in a microcentrifuge (10,000×g). 2X Reaction Buffer was added to the supernatant, and the supernatant proteins were incubated for 1-2 hours at 37°C with 200 µM DEVD-p-nitroanilide (pNA). The color change was mea sured using a microtiter plate reader at 405 nm.
Western blot analysis
Cell extracts were prepared with radioimmunoprecipitation assay lysis buffer (ROCKLAND Immunochemicals, Pottstown, PA, USA) and protein concentrations were determined using the BCA Protein Assay Kit (Thermo Scientific, Rockford, IL, USA). Samples were diluted in 5×sodium dodecyl sulfate (SDS) gel-loading buffer (60 mM Tris-HCl pH 6.8, 25% glycerol, 2% SDS, 14.4 mM 2-mercaptoehanol and 0.1% bromophenol blue) and boiled at 95°C for 10 minutes. Protein lysates (30 μg) were separated by 12% SDS-polyacrylamide gel electrophoresis. After transferring to polyvinylidene difluoride membrane (Millipore, Bed ford, MA, USA) at a constant voltage of 10 V for 27 minutes, membranes were incubated with 5% albumin bovine in Tris-buffered saline plus 0.1% Tween-20 (TBST) at RT for 1 hour. The blots were incubated overnight with primary antibodies against p-ERK1/2, ERK1/2, p-p38 MAPK, p38 MAPK, p-SAPK/JNK, SAPK/JNK. Next, the membranes were washed in TBST and incubated with secondary goat anti-rabbit IgG-HRP at 1:2,000 dilution at RT for 1 hour. Detection of a signal was performed with the ECL plus kit. The intensities of the western blot bands were measured by densitometry using Multi Gauge Software (Fuji Photofilm, Tokyo, Japan).
Statistical analysis
Data were analyzed using the IBM SPSS Statistics ver. 22.0 (IBM Co., Armonk, NY, USA). Examined data were assessed using t tests and analysis of variance. In each test, the data were expressed as the mean±standard deviation with Excel 2007. Statisti cal significance was defined as when the P value was less than 0.05.
Results
Cell viabilities
The MTT assay was performed and measure the relative cell viabilities after treatment with rHuEPO at different concentration to determine the most effective concentration of the drug for cell viability (Fig. 1) . The results showed that the best cell viabilities were achieved at EPO 0.1 U/mL and 10 U/mL in the neuronal cells and the astrocytes respectively.
Detection of apoptosis in the neuronal cells and astrocytes
The TUNEL assay was performed by flow cytometry in neuronal cells (Fig. 2 ) and the astrocytes (Fig. 3) to determine whether EPO reduces apoptotic rates against a hypoxic injury. Hypoxia induces apoptosis in both neuronal cells and astrocytes. This results showed that the astrocytes were more resistant to hypoxic injury compared with the neuronal cells. While the apoptotic rates were 9.91% and 7.12% in the neuronal cells and astrocytes, respectively after 6-hour exposure to hypoxia, as time progresses till 15 hours, the neuronal cells undergo more profound apoptosis (61.07%) compared with the astrocytes (10.54%). After 6-hour exposure to hypoxia, the apoptotic rate was not reduced and rather increased with EPO pretreatment (9.91% in the H and 16.44% in the H+EPO) in the neuronal cells. However, after 15-hour exposure to hypoxia, the apoptotic rate was reduced by about two-third with EPO pretreatment (61.07% in the H and 42.93% in the H+EPO, P<0.05).
In the astrocytes, apoptotic rates were similar with EPO pretreatment after 6 hours after hypoxia exposure (7.12% in the H and 6.01% in the H+EPO). After 15-hour exposure to hypoxia, the apoptotic rate was decreased with EPO pretreatment (10.54% in the H and 6.43% in the H+EPO, P<0.05).
Activation of DEVDspecific caspase3
The effects of EPO on neuronal apoptosis induced by hypoxia were evaluated by measuring cleaved caspase-3 activity (Fig. 4) . In both neuronal cells and astrocytes, the caspase-3 activity was significantly increased after 15 hours exposure to hypoxia (P< 0.05). Pretreatment with EPO attenuates significantly this increase of caspase-3 activity induced by hypoxia in both cell groups (P< 0.05).
Activation of MAPK pathway in the neuronal cells and astro cytes
Western blot was performed at baseline, 6 hours, and 15 hours to examine the expressions of MAPKs and phosphorylated MAPKs to explore the relationship between the effects of EPO on survival and the MAPK pathways in the neuronal cells (Fig. 5 ) and the astrocytes (Fig. 6 ).
In the neuronal cells, the phosphorylation of ERK1/2 and SAPK/JNK was gradually increased with a peak at 15 hours ex- The percentage of total apoptotic cells is shown in the histogram. N, normoxic group; 6H, hypoxic group that was exposed to hypo xia for 6 hours; 6H+erythropoietin (EPO), hypoxic group pretreated with EPO that was exposed to hypoxia for 6 hours; 15H, hypoxic group that was exposed to hypoxia for 15 hours; 15H+EPO, hypoxic group pretreated with EPO that was exposed to hypoxia for 15 hours. In the astrocytes, the phosphorylation of ERK1/2 and SAPK/ JNK was increased after both 6 hours and 15 hours exposure to hypoxia. The phosphorylation of p38 MAPK was increased after 6-hour exposure to hypoxia and then decreased after 15-hour exposure to hypoxia. Pretreatment with EPO did not affect the phosphorylation of JAPK/JNK whereas significantly attenuates a reduction in the phosphorylation of ERK1/2 and p38 MAPK after 15-hour exposure to hypoxia (P<0.05).
Discussion
In this study, the effects of EPO on hypoxia-induced neuronal apoptosis and the underlying mechanisms involving MAPK pathways are examined using cultured neuronal cells and astrocytes.
Hypoxia induced apoptosis in both the neuronal cells and astrocytes with caspase-3 activation. Since the caspase-dependent cell damage after neonatal hypoxic injury does not peak until 12-24 hours 1) , the degree of apoptosis was correlated with caspase-3 activation showing significant neuronal cell loss after 15-hour exposure to hypoxia. Although the astrocytes were more resistant to hypoxia-induced apoptosis, the concentration of rHuEPO for maximal cell viability was 10 fold higher than that of the neuronal cells. As the neuronal cells showed less viability at higher concentration, and the astrocytes did not show benefits at the lower concentration, the cytoprotective dose for the neuronal Time (hr) Fig. 3 . Apoptosis in the astrocytes. Apoptosis was assessed by the quantification of BrdU-FITC-labeled DNA breaks using a flow cytometrybased terminal deoxynucleotidyl transferase dUTP nick end labeling assay in the astrocytes. Two dyes, propidium iodide (total cellular DNA) and fluorescein (apoptotic cells), were used. (A) Apoptotic cells can be seen in the B2 gate. (B) The percentage of total apoptotic cells is shown in the histogram. N, normoxic group; 6H, hypoxic group that was exposed to hypoxia for 6 hours; 6H+erythropoietin (EPO), hypoxic group pretreated with EPO that was exposed to hypoxia for 6 hours; 15H, hypoxic group that was exposed to hypoxia for 15 hours; 15H+EPO, hypoxic group pretreated with EPO that was exposed to hypoxia for 15 hours. *P<0.05, statistically significant vs. N group. . Pretreatment with rHuEPO decreased apoptotic rates in both neuronal cells and astrocytes after 15-hour exposure to hypoxia accompanying caspase-3 inactivation indicating that rHuEPO exerts neuroprotective effect via caspase-3 dependent mechanisms. Also, this study showed that rHuEPO attenuated ERK1/2 activation induced by 15-hour hypoxia suggesting the neuroprotective effect of EPO seems to be transduced via the ERKmediated mechanism.
Since the activation of SAPK/JNK was not affected in both neuronal cells and astrocytes by rHuEPO pretreatment in this study, this result supports the SAPK/JNK pathways themselves may not be involved in the EPO-mediated neuroprotective mechanism. In agreement with this study, Kwon et al. 25) also re ported that pSAPK/JNK was not altered by EPO treatment in C6 cells. In the case of p38 MAPK, rHuEPO decreased activation of p38 MAPK in only the astrocyte after exposure of 15-hour hypoxia. These results suggest that the response of each MAPK are cellspecific. The activation of p38 MAPK tended to decrease as time progressed regardless of rHuEPO pretreatment while the role of EPO in p38 MAPK pathway in astrocytes does not seem to be important pathways for EPO-neuroprotection.
ERK is one of the MAPK pathways, and activated by growth factors, mitogen stimuli, glutamate receptor activation and intracellular calcium increases 26) . The effect of ERK pathway on neuroprotection was diverse in different experimental models. Some reports showed neuroprotection with ERK activation 1, 25, 27) and others showed neuroprotection with ERK inhibition 28, 29) . The role of ERK activation may be via multiple upstream signaling mechanisms depending on factors such as cell type, culture conditions, and the injurious mechanisms 1) . Neuronal apoptosis accompanied ERK activation in Perfluorohexane sulfonate induced injury with a persistent increase in intracellular calcium while intracellular calcium-mediated ERK inhibition reduced apoptosis 28) . Brain-derived neurotrophic factor (BDNF) showed neuroprotective effect through ERK activation against neonatal HIE brain injury in vivo 1, 30) . They showed BDNF influ enced on ERK pathways in only neuronal cells and not in astro cytes and oligodendrocytes. This result supports the cell-type specific ERK activation. In this study, EPO interfered with ERK activation after hypoxic injury in both neuronal cells and astro cytes. Yuan et al. 31) reported that the ERK phosphorylation was significantly higher in the HI rats and significantly much higher in the HI+EPO rats. However, they measured ERK activation shortly after HI injury (at 60 minutes and 90 minutes). Short, transient activation by growth factors under a physiologic condition, ERK activation are associated with neuroprotection while prolonged, persistent activation could induce cell death 27) . In ischemic tolerance model, neuronal EPOR activated only Akt pathways, not ERK or p38 pathways 32) while hypoxic preconditioning involves ERK activation 27) . These results support the stimulus or injury-dependent ERK activation. Taken together, trophic factors such as BDNF or EPO might initiate transient ERK activation associated with neuroprotective mechanisms. In con trast, prolonged, persistent ERK activation after HI injury might initiate mechanisms of cell death. Indeed, alteration in ERK sig naling after brain injury may be distinct from trophic factor sti mulation. Due to lack of measurement for the baseline ERK acti vation after EPO pretreatment, the initial increase in ERK pho s phorylation was not determined. However, the study suggests that pretreatment of EPO attenuated the pathologic ERK activ ation induced by prolonged, persist activation after hypoxic injury and led to improving cell survival.
Since this study did not use the ERK inhibitor, it was not determined whether the ERK inhibition initiated by EPO was direct causative mechanisms for neuroprotection or resultant indirect phenomenon. Kwon et al. 25) showed that the inhibitors of pp38
MAPK and pERK abolished the EPO on cytotoxicity of staurosproine. Therefore, the possibility of ERK pathways in regulating apoptosis is still present.
In conclusion, rHuEPO exerts neuroprotective effects against hypoxic injury reducing apoptosis by caspase-dependent mechanisms. Pathologic, persistent ERK activation after hypoxic injury may attenuate by pretreatment EPO supporting that EPO may regulate apoptosis by affecting ERK pathways. This study may contribute to determining the possible mechanisms of the role of each MAPK pathways in the cytoprotective effect of rHuEPO.
Time (hr)
Time ( 
Conflict of interest
No potential conflict of interest relevant to this article was reported.
